cysteuze fibrose (CF) chronische ontsteking van de longen
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Controls: Age > 18 years and younger than 50 years Healthy without indications of any inflammatory disease Written informed consent;CF patients without treatment wtih corticosteroids Age > 18 and younger than 50 years Diagnosis of CF by clinical symptoms and positive sweat tests (sweat Cl- concentration > 60 mmol/l) and/or disease causing mutation(s) in the CFTR gene Being clinically stable and on steady concomitant therapy at least four weeks prior to the study FEV1 > 30% of predicted written informed consent;CF patients on treatment wtih corticosteroids Diagnosis of CF by clinical symptoms and positive sweat tests (sweat Cl- concentration > 60 mmol/l) and/or disease causing mutation(s) in the CFTR gene Being clinically stable and on steady concomitant therapy at least four weeks prior to the study FEV1 > 30% of predicted inhalation of fluticasone proprionate (or equivalent) >400 microg total daily for at least 2 weeks prior to the study. written informed consent
Exclusion criteria
Exclusion criteria: Any infection Smoking Auto-immune disease Use of medication, excluding: anticonceptives and pain killers (used less than once a week) exuberant alcohol consumption (for males > 36 glasses per week, for females > 24 glasses per week) drugs abuse History of cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study parameters/outcome of the study: Granulocyte post-mitotic pool transit times and lifespans in blood and sputum in normal healthy volunteers and CF patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary study parameters/outcome of the study (if applicable): None | — |
Countries
Netherlands
Outcome results
None listed